药物对比
Canagliflozin vs Gliclazide
比较Canagliflozin（Invokana，SGLT2抑制剂）与Gliclazide（磺脲类）治疗2型糖尿病：机制、心血管/肾脏获益、低血糖风险、体重影响与安全性。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when choosing a second-line oral agent after metformin in type 2 diabetes, especially with CV disease, CKD, or hypoglycemia concerns.
结论
Canagliflozin typically provides broader cardiorenal protection and metabolic advantages over Gliclazide, though cost and individual factors matter.
全部药物对比